期刊文献+

安立泽联合胰岛素治疗单独胰岛素降糖欠佳的高龄2型糖尿病患者临床观察 被引量:2

The Clinical Observation of An Li ze Combined with Insulin Therapy for Elderly Type 2 Diabetes Patients with Poor Hypoglycemic Effects of Insulin Alone
原文传递
导出
摘要 目的:观察安立泽应用于单独胰岛素治疗血糖控制欠佳的高龄2型糖尿病患者的疗效及安全性。方法:200例高龄2型糖尿病胰岛素降糖欠佳的患者(空腹血糖控制在7.8-13.9mmol/L范围内),随机分成对照组和治疗组,对照组采用胰岛素加安慰剂治疗80例;治疗组120例,分为A、B、C三组,每组40例,A、B、C三组分别在继续应用胰岛素治疗的基础上加服安立泽4mg/d、5mg/d、6mg/d,疗程三个月。观测治疗组和对照组治疗前后FPG及PPG、HbA1C、BMI和胰岛素用量的改变及治疗的安全性。结果:对照组和治疗组治疗前的各指标无明显差异(P>0.05);A、B、C三组在治疗后1个月和3个月FPG、PPG、HbA1C均有明显的下降(P<0.05,P<0.01),而对照组治疗前后FIG、PPG、HbA1C略有下降,差异不明显(P>0.05);A、B、C三组胰岛素的用量及体重指数较治疗前均略有下降,三组间无显著性差异;对照组和治疗组的不良反应发生率无显著差异。结论:对高龄2型糖尿病单用胰岛素治疗血糖控制欠佳的患者,加用安立泽治疗,可使糖尿病相关指标得以良好的控制,减少糖尿病患者每日胰岛素用量,临床毒副作用较小。 Objective: To observe the efficacy and safety of An Lize combined with insulin therapy for elderly type 2 diabetes patients with poor hypoglycemic effects of insulin alone. Methods: 200 cases of elderly type 2 diabetic patients with poor insulin hypoglycemic (fasting blood glucose control in 7.8-13.9mmol/L range) were randomly divided into control and treatment groups. 80 cases in Control group were treated with insulin plus placebo therapy, treatment group of 120 patients, divided into A, B, C three groups, each group 40 cases, A, B, C three groups were treated with continued application of insulin therapy, additionally serving An Lize 4 mg/d, 5 mg/d, 6 mg/d, three-month course of treatment. FPG and PPG, HbA1C, BMI and insulin dosage changes and safety of the treatment of the two groups before and after treatment were observed. Results: The two groups before treatment showed no significant difference (P〉 0.05), after treatment in a month, and 3 months, the FPG, PPG and HbA1C of A, B, C three groups were significantly decreased (P 〈0.05, P 〈0.01), while the control group before and after treatment FIG, PPG, HbA1C decreased slightly, which had no significant difference (P〉 0.05); A, B, C three groups of insulin dosage and body mass index decreased slightly compared with before trealment, the three groups showed no significant difference; the incidence of adverse reactions of control group and the treatment group had no significant difference. Conclusion: To those elderly type 2 diabetes patients, who cannot simply use insulin to control blood sugar, plusing An Lize treatment can control of diabetes related indicators, reduce diabetes daily insulin dosage, and produce small clinical side effects.
机构地区 成都军区总医院
出处 《现代生物医学进展》 CAS 2014年第4期735-738,共4页 Progress in Modern Biomedicine
关键词 安立泽 胰岛素 高龄2型糖尿病患者 An Li Ze Insulin Elderly patients with type 2 diabetes
  • 相关文献

参考文献19

  • 1Ahren B. Use ofDPP-4 inhibitors in type 2 diabetes: focus on Sitaglip- tin [J]. Diabetes Metab Syndr Obes, 2010, 3:31-41.
  • 2Williams-Herman D, Engel SS, Round E, et al. Safety and tolembility of sitagliptin in clinical studies: a pooled analysis of data from 10246 patients with type 2 diabetes [J]. BMC Endocr Disord, 2010, 10:7-9.
  • 3Meneilly GS, Tessier D. Diabenes in elderly adults [J].J Gerontol A Biol Sci IVied, 2001, 56(1): 5-13.
  • 4陆菊明.2型糖尿病治疗新药沙格列汀的药理及临床评价[J].中国新药杂志,2011,20(21):2039-2043. 被引量:40
  • 5Henry RR, Smith SR, Schwartz SL, et al. Effects of saxagliptin onβ-cell stimulation and insulin secretion in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2011, 13(9): 850-858.
  • 6National Institute for health and clinical excellence. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes [J]. NICE short clinical guideline 87. London: NICE, 2009.
  • 7Uk prospective Diabetes study (UkPDs) Group Uk prospective disabetes studyl 6 overview of 6yeras, therapy of type 2diabetes: apro- ~ressive disesease[J]. Diabetes, 1995, 44:1249-1258.
  • 8王鉴,顾鸣敏.线粒体基因突变与糖尿病的相关性研究进展[J].现代生物医学进展,2012,12(24):4752-4756. 被引量:8
  • 9Mohan V, Yang W, Son HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India and Korea[J]. Diabetes Res Clin Pract, 2009, 83(1): 106-116.
  • 10American Diabetes Association Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes [J]. Diabetes Care, 2005, 28:1245-1249.

二级参考文献36

  • 1Gerbitz KD, van den Ouweland JMW, Massen JA, et al. Mitochondrial diabetes mellitus: a review [J]. Biochimica et Biophysica Acta, 1995, 1271(1):253-260.
  • 2Van den Ouweland JM, Lemkes HH, Ruitenbeek W, et al. Mutation in mitochondrion t-RNALeu(URR) gene in a large pedigree with mater- nally transmitted type II diabetes melitus and deafness [J]. Nat Genet, 1992, 1 (5): 368-371.
  • 3Taylor RW, Tumbull DM. Mitochondrial DNA mutations in human disease [J]. Nat Rev Genet, 2005, 6(5): 389-402.
  • 4Petersen KF, Dufour S, Befroy D, et al. Impaired mitochondreial activ- ity in the insulin-resistant offspring of patients with type 2 diabetes [J]. N Engl J Med, 2004, 350:644-671.
  • 5Guillausseau PJ, Massin P, Dubois-LaForgue D, et al. Maternally in- herited diabetes and deafness: a multicenter study [J]. Ann Intern Med, 2001, 134:721-728.
  • 6Maassen JA. Mitochondrial diabetes, diabetes and the thiamine-re- sponsive megaloblastic anaemia syndrome and MODY-2: Diabetes with common pathophysiology? [J]. Panminerva Med, 2002, 44: 395-400.
  • 7Ohkubo K, Yamano A, Nagashima M, et al. Mitochondrial gene muta- tions in the tRNA (Leu (UUR)) region and diabetes: prevalence and clinical phenotypes in Japan [J]. Clin Chem, 2001, 47:1641-1648.
  • 8Wallace DC. Mitochondrial diseases in man and mouse [J]. Science, 1999, 283:1482-1488.
  • 9Maassen JA, q" Hart LM, Van Essen E, et al. Mitochondrial Diabetes: Molecular Mechanisms and Clinical Presentation [J]. Diabetes, 2004, 53 (Suppl 1): S103-109.
  • 10'T Hart LM, Jansen J J, Lemkes HH, et al. Heteroplasmy levels of a mitochondrial gene mutation associated with diabetes melllitus de- crease in leucocyte DNA upon aging [J]. Hum Mutat, 1996, 7: 193-197.

共引文献737

同被引文献12

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部